308080 — ViGenCell Cashflow Statement
0.000.00%
- KR₩62bn
- KR₩25bn
- KR₩279m
Annual cashflow statement for ViGenCell, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -10,455 | -11,114 | -17,393 | -17,875 | -14,056 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 4,399 | 1,466 | 1,672 | -1,291 | -659 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -3,017 | -25.2 | 1,714 | -199 | 188 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -8,192 | -7,955 | -11,089 | -15,267 | -10,895 |
Capital Expenditures | -1,775 | -15,493 | -13,684 | -1,024 | -113 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -874 | -53,236 | 2,811 | 25,356 | 4,225 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -2,649 | -68,729 | -10,872 | 24,332 | 4,113 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -379 | 103,555 | -1,819 | 297 | 169 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -11,220 | 26,872 | -23,784 | 9,354 | -6,621 |